SCHERING AG RECEIVES EU APPROVAL FOR NOVEL CONTRAST AGENT VASOVIST

Schering AG, Germany recently announced that Vasovist (gadofosveset trisodium), its novel contrast agent for magnetic resonance angiography, has been approved by the European Commission in all 25 member states of the EU. Vasovist is an innovative blood pool contrast agent indicated for visualization of abdominal or limb vessels in patients with known or suspected vascular disease such as stenosis and aneurysms.
PRNewswire